Physician profile
Catherine E Grimsley
NPI 1609543933
$1,770.37
in general payments reported to CMS, 2019-2025
20 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $533 · 2023: $441 · 2024: $522 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $740.43 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.86 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $155.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $137.06 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $74.57 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $72.25 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $54.72 | 2025 | Austedo Xr |
| Corium, LLC | $49.88 | 2023-2024 | Azstarys |
| Novo Nordisk INC | $46.96 | 2024-2025 | Wegovy |
| Alkermes, INC. | $38.50 | 2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $34.43 | 2024 | Xelstrym, Secuado |
| Amgen INC. | $32.80 | 2024-2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $32.68 | 2022 | |
| Pfizer INC. | $20.53 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.56 | 2025 | Keveyis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.43 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $16.98 | 2024 | Auvelity |
| Mylan Specialty L.P. | $16.03 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.30 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Grimsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.